pharma · Systemic Sclerosis · Nonalcoholic Steatohepatitis · CMMB
Chemomab Therapeutics
Chemomab Therapeutics is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker CMMB. Primary therapeutic focus areas include Systemic Sclerosis, Nonalcoholic Steatohepatitis, Nonalcoholic F
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
CMMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 4
- Patents
- 4
Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Phase 1 · small molecule · Nonalcoholic Fatty Liver Disease
Anti-human CCL24 monoclonal antibody (CM-101) - Part One for Nonalcoholic Fatty Liver Disease is a Phase 1 program (small_molecule) at Chemomab Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CM-101-I-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chemomab Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Nonalcoholic Fatty Liver Disease
- Status
- completed
- Trials
- 1